OpenAI Rejects Apple Trade Secret Theft Claims 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
France Targets Shein, Temu With Fast-Fashion Fees 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Add as a preferred source on Google
NEW HAVEN, Conn., March 13, 2018 -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, announced today that it has cancelled its presentation at the Cowen & Company 38th Annual Health Care Conference scheduled for Wednesday, March 14, 2018 in Boston, due to the severe weather that has been forecast for the region. Company President and CEO Dan Wechsler had been scheduled to speak.
Melinta will post the presentation material to the Events & Presentations section of its Investors webpage at http://ir.melinta.com/events.
About Melinta Therapeutics
Melinta Therapeutics, Inc. is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new and better therapeutic solutions. Its four marketed products include Baxdela™ (delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. It also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections. Visit www.melinta.com for more information.
For More Information:
Media Inquiries:
Amra Maynard
(917) 302-2702
[email protected]
Investor Inquiries:
Lisa DeFrancesco
(847) 681-3217
[email protected]
Raj Mistry
(312) 801-2051
[email protected]
